We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Helix BioPharma Files IND for a U.S. Phase I Clinical Study of L-DOS47
News

Helix BioPharma Files IND for a U.S. Phase I Clinical Study of L-DOS47

Helix BioPharma Files IND for a U.S. Phase I Clinical Study of L-DOS47
News

Helix BioPharma Files IND for a U.S. Phase I Clinical Study of L-DOS47

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Helix BioPharma Files IND for a U.S. Phase I Clinical Study of L-DOS47"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

L-DOS47 is designed to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

L-DOS47 is the Company's first therapeutic immunoconjugate drug candidate under development based upon its novel DOS47 technology, which is designed to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction. L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).

"This is a significant milestone for Helix. We are seeking approval to commence the much anticipated human clinical testing stage of development for this important new drug candidate," said John Docherty, president of Helix BioPharma Corp. "Having previously completed a pre-IND meeting with the FDA to identify its requirements for this IND filing, we are hoping that the review and approval process will proceed successfully."

The IND review process typically requires 30 days, during which the FDA will decide if an applicant is permitted to proceed with its proposed clinical trial.

Advertisement